HOXD13 and cancer: Then, because the combination of tumor vaccine and ICIs reported benefits in clinical and pre-clinical trials for cancer therapy, the hypothesis of the sPD-1-TWIST1 vaccination combined with anti-CTLA-4 was also tested, resulting in elicited long-lasting T cell immunity and mesothelioma reduction [150].